CANC Holdings — Tema Oncology ETF
All 57 reported holdings of Tema Oncology ETF (CANC) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Revolution Medicines Inc | 7.73% | $13.61M |
| Eli Lilly & Co | 4.82% | $8.49M |
| Roche Holding AG | 4.21% | $7.42M |
| Cogent Biosciences Inc | 4.10% | $7.22M |
| Novartis AG | 4.03% | $7.10M |
| Immunome Inc | 3.91% | $6.89M |
| Celcuity Inc | 3.58% | $6.31M |
| Merck & Co Inc | 3.57% | $6.29M |
| AstraZeneca PLC | 3.54% | $6.23M |
| Nuvalent Inc | 3.37% | $5.93M |
| Bristol-Myers Squibb Co | 3.30% | $5.81M |
| Legend Biotech Corp | 2.99% | $5.27M |
| AbbVie Inc | 2.81% | $4.94M |
| Exelixis Inc | 2.78% | $4.89M |
| Bridgebio Pharma Inc | 2.75% | $4.85M |
| Johnson & Johnson | 2.55% | $4.48M |
| CG oncology Inc | 2.43% | $4.28M |
| Genmab A/S | 2.37% | $4.18M |
| Ideaya Biosciences Inc | 2.27% | $4.00M |
| Amgen Inc | 2.11% | $3.71M |
| Zai Lab Ltd | 1.98% | $3.48M |
| BeOne Medicines Ltd | 1.88% | $3.31M |
| Zymeworks Inc | 1.51% | $2.65M |
| Enliven Therapeutics Inc | 1.31% | $2.30M |
| Relay Therapeutics Inc | 1.28% | $2.26M |
| Halozyme Therapeutics Inc | 1.23% | $2.17M |
| Summit Therapeutics Inc | 1.21% | $2.12M |
| Arcus Biosciences Inc | 1.20% | $2.11M |
| Gilead Sciences Inc | 1.12% | $1.98M |
| Immatics NV | 1.12% | $1.97M |
| First American Treasury Obliga | 1.09% | $1.92M |
| Erasca Inc | 1.08% | $1.90M |
| Nuvation Bio Inc | 1.07% | $1.89M |
| AnaptysBio Inc | 0.99% | $1.74M |
| UroGen Pharma Ltd | 0.93% | $1.65M |
| Guardant Health Inc | 0.81% | $1.42M |
| Syndax Pharmaceuticals Inc | 0.80% | $1.41M |
| Corvus Pharmaceuticals Inc | 0.76% | $1.35M |
| Regeneron Pharmaceuticals Inc | 0.75% | $1.31M |
| ArriVent Biopharma Inc | 0.73% | $1.29M |
| Chugai Pharmaceutical Co Ltd | 0.67% | $1.17M |
| Iovance Biotherapeutics Inc | 0.65% | $1.15M |
| Inhibrx Biosciences Inc | 0.60% | $1.06M |
| Olema Pharmaceuticals Inc | 0.60% | $1.05M |
| Cullinan Therapeutics Inc | 0.59% | $1.03M |
| Natera Inc | 0.54% | $946.64K |
| First Tracks Biotherapeutics I | 0.53% | $932.37K |
| Immunocore Holdings PLC | 0.51% | $891.23K |
| BridgeBio Oncology Therapeutic | 0.48% | $837.25K |
| CytomX Therapeutics Inc | 0.47% | $824.35K |
| HUTCHMED China Ltd | 0.44% | $776.57K |
| Arvinas Inc | 0.43% | $755.43K |
| Janux Therapeutics Inc | 0.43% | $751.71K |
| Adlai Nortye Ltd | 0.30% | $529.59K |
| Tyra Biosciences Inc | 0.30% | $527.21K |
| ORIC Pharmaceuticals Inc | 0.28% | $489.91K |
| SELLAS Life Sciences Group Inc | 0.22% | $378.94K |
CANC overview: performance, fees, allocation and SEC filings